EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A plasma protein signature for cerebral amyloid angiopathy

Alpana Singh, Marisa N Denkinger, Antoine Leuzy, Kari Dieckhoff, Jame Liu, Taina M Marques, Edwin Monuki, Craig Stark, Joshua D Grill, Christy Hom, David Sultzer, Eric Doran und 13 weitere

Acta Neuropathologica · 2026

DOI: 10.1007/s00401-026-03030-5 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Acta Neuropathologica, 2026. Verfasst von Alpana Singh und 24 weiteren Autor:innen. Beteiligte Einrichtung: Fluid Biomarker Program, Banner Sun Health Research Institute, 10515 West Santa Fe Drive, Sun City, AZ, 85351, USA. Hauptthemen laut MEDLINE: Cerebral Amyloid Angiopathy. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 82 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NINDS NIH HHS, NIA NIH HHS, Arizona Department of Health Services.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cerebral amyloid angiopathy (CAA) is a cerebrovascular disorder characterized by the deposition of amyloid-β (Aβ) in the walls of leptomeningeal and cortical blood vessels that increases risk of intracerebral hemorrhages and progressive cognitive decline. More than 90% of individuals with Alzheimer’s disease (AD) exhibit some level of CAA. Notably, in the new era of disease-modifying treatments for AD, CAA is a significant risk factor for amyloid-related imaging abnormalities (ARIA), an adverse event associated with anti-amyloid treatments. Therefore, there is great need for accessible, reliable and accurate in vivo biomarkers (e.g., blood-based) to improve antemortem identification of CAA that would improve risk stratification and reduce symptomatic ARIA. In this study, we employed the Nucleic Acid-Linked Immuno-Sandwich Assay (NULISA™) central nervous system panel for exploratory biomarker quantification in antemortem plasma of participants with neuropathological assessments for CAA from the Banner Sun Health Research Institute Brain and Body Donation Program ( N = 251) and independently validated in the University of California Irvine Alzheimer Disease Research Center cohort ( N = 110). We evaluated the differential protein expression in antemortem plasma sample taken < 5 years (mean 1.76 ± 1.3) from death using a logistic regression model. We further compared multi-biomarker models and found that a combination of CRP, IL4, CCL11, NPY and PDLIM5, plus demographic covariates showed an area under the curve (AUC) of 0.90 (95% CI 0.86–0.94) to identify neuropathologically confirmed CAA in the discovery cohort. In our independent replication, the antemortem plasma signature performed better than the basic demographics model showing a potential to predict CAA. The exploration and validation in antemortem plasma indicate that a multi-analyte panel, when combined with in vivo blood biomarkers for AD pathology, may be capable of identifying the presence of CAA and could have an meaningful impact on the clinical evaluation of patients under the investigation for cognitive decline. Further developments in biomarkers for this condition are crucial so that CAA identification could inform treatment decisions by highlighting ARIA risk.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cerebral Amyloid AngiopathyHumansFemaleBiomarkersMaleAgedAmyloid beta-PeptidesAged, 80 and overBrain

Stichwörter der Autor:innen

ARIABlood biomarkersCerebral amyloid angiopathyNeuropathology

Substanzen

BiomarkersAmyloid beta-Peptides

Autor:innen und Institutionen

  • Fluid Biomarker Program, Banner Sun Health Research Institute, 10515 West Santa Fe Drive, Sun City, AZ, 85351, USA.
  • Department of Pathology and Laboratory Medicine, University of California, Irvine, CA, 92697, USA.
  • Institute for Memory Impairments and Neurological Disorders, University of California, Irvine, CA, 92697, USA.
  • Department of Neurobiology and Behavior, University of California, Irvine, CA, 92697, USA.
  • Department of Psychiatry and Human Behavior, University of California, Irvine, CA, 92697, USA.
  • Department of Pediatrics, University of California, Irvine, CA, 92697, USA.

Förderung

  • NINDS NIH HHS
  • NIA NIH HHS
  • Arizona Department of Health Services
  • Arizona Biomedical Research Commission
  • National Institute of Neurological Disorders and Stroke
  • National Institute on Aging
  • University of Gothenburg

Zitieren

APA

Singh, A., Denkinger, M. N., Leuzy, A., Dieckhoff, K., Liu, J., Marques, T. M., Monuki, E., Stark, C., Grill, J. D., Hom, C., Sultzer, D., Doran, E., Lott, I., Wood, K., Gawronski, B., Gonzalez, L., Choudhury, P., Atri, A., Beach, T. G., …, & Ashton, N. J. (2026). A plasma protein signature for cerebral amyloid angiopathy. Acta Neuropathologica. https://doi.org/10.1007/s00401-026-03030-5

Vancouver

Singh A, Denkinger MN, Leuzy A, Dieckhoff K, Liu J, Marques TM, et al. A plasma protein signature for cerebral amyloid angiopathy. Acta Neuropathologica. 2026. doi:10.1007/s00401-026-03030-5

BibTeX
@article{Singh2026,
  author = {Singh, Alpana and Denkinger, Marisa N and Leuzy, Antoine and Dieckhoff, Kari and Liu, Jame and Marques, Taina M and Monuki, Edwin and Stark, Craig and Grill, Joshua D and Hom, Christy and Sultzer, David and Doran, Eric and Lott, Ira and Wood, Kevin and Gawronski, Brianna and Gonzalez, Lourdes and Choudhury, Parichita and Atri, Alireza and Beach, Thomas G and Serrano, Geidy E and Sajjadi, S Ahmad and Van Keuren-Jensen, Kendall and Reiman, Eric M and Head, Elizabeth and Ashton, Nicholas J},
  title = {A plasma protein signature for cerebral amyloid angiopathy},
  journal = {Acta Neuropathologica},
  year = {2026},
  doi = {10.1007/s00401-026-03030-5}
}
Kostenlos starten →